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INTRODUCTION
Accumulating evidence supports an association between angiogenesis and tlie processes of tumor invasion and metastasis. In this way, several angiogenic factors and their receptors have been identified as important mediators of angiogenesis (1) . We as well others have accumulated evidence suggesting that HEREGULIN (HRG), a growth factor involved in the progression of breast cancer to a more malignant phenotype (2) (3) (4) , also is a potent stimulator of in vitro growth of a special blood vessel cells found in the umbilical cord, called HUVEC (Human Umbilical Vein Endothelial Cells). Hence, HRG pathway can enhance tumor neovascularization and this up-regulation of angiogenesis may contribute to a more aggressive disease. Significantly, we have also demonstrated that the grovirth factor-inducible immediate-eariy gene CCN1 (Cysteine-rich angiogenic protein 61; CYR61) is a down-stream effector of HRG-induced breast cancer chemomigration and metastasis, probably through interactions with the Ovps integrin receptor (5) . CGN1 stimulates chemotaxis in endothelial cells and induce neovascularization in vivo (6) . Moreover, we have shown that CCN1 overexpression in tumor cells enhances tumorigenicity by increasing tumor size and vascularization (7) . In this regard, we have determined previously that CCN1 gene expression is elevated in highly invasive and metastatic human breast cancer cells and tumor biopsies (5) . Accordingly, CCN1 overexpression is correlated with more advance stage of malignancy in patients samples (7) . Taken together, these findings prompted us to hypothesize that HRG (directly or indirectly through GCN1) is an important regulator of the vascular compartment in breast cancer with stimulating effects on tumor neovascularization which, in turn, promotes progression and dissemination of breast carcinoma.
We recently showed that in ovariectomized nude mice brast carcinoma cells secreting HRG promoted more vascularized tumors (9) . We demonstrated that one of the mechanisms by which HRG achieved this aggressive phenotype was mediated via an increase in the expression of Vascular Endothelial Growth Factor (VEGF), a key tumor angiogenic factor. In MCF-7/HRG-derived tumors, a great increase in VEGF expression was observed by inmunohistochemistry staining with anti-VEGF antibody. These results were further confirmed by an ELISA assay, demonstrating a 3-to 8-fold increase in VEGF expression was observed in the conditioned media from HRGtransfected cells. Of interest, in our experiments there was a positive correlation between the increase in the ability of the HRG transfectants to secrete VEGF and the levels of HRG expression. Consistent with this finding, HRG has been shown to selectively up-regulate VEGF secretion in both cancer and HUVEC cells and to stimulate in vivo angiogenesis (10) . Nevertheless, some of the effects that were observed in vivo were probably mediated indirectly via the up-regulation of other genes in an autocrine/paracrine manner. For example, the expression of CCN1 was significantly up-regulated in the MCF-7/HRG-derived tumors. Accordingly, we found that CCNI-induced tumors in ovariectomized athymic nude mice did resemble human invasive carcinomas with increased vascularization and overexpression of VEGF (7) .
An important issue that arises from the contribution of VEGF to breast cancer neovascularization is an understanding of the mechanism(s) that regulate VEGF expression. Such mechanisms are important not only for VEGF signaling in breast cancer cells, but also for angiogenesis as well. Clearly, hypoxia is a strong inducer of VEGF transcription and mRNA stability (11) , but other factors are likely to be involved. Of note, our finding that the a«p3 integrin can promote the survival of breast carcinoma cells in stress conditions such as chemotherapy treatment is intriguing (12) , and raised the novel possibility that a specific integrin avPs, which has been implicated in breast cancer progression (13) , could play an active role regulating VEGF secretion in HRG-overexpressing breast cancer cells.
BODY
The aim 2 in the proposed study was to determine the effect of HRG on the secretion of angiogenic factors and elucidate the contribution of HRG to the angiogenic potential of breast carcinomas. Since VEGF appears to be an essential angiogenic factor for the progression of many solid tumors, including breast carcinomas, we examined the role of HRG on the regulation of the VEGF secretory isoform, VEGFies, in relation to the expression level of either CCN1 (CYR61) or HER-2/neu oncogene in human breast cancer cells.
Several oncogenes {HER-2/neu), growth factors (HRG), hormones and hypoxia have been shown to upregulate VEGFi65. We previously demonstrated that CCN1 is differentially expressed in breast cancer cells overexpressing HRG, a member of the epidermal growth factor-like growth factor family that regulates angiogenesis via up-regulation of VEGFi65 expression and secretion (5, 10) . More recently, we found that CCN1-induced tumors in ovariectomized athymic nude mice did resemble human invasive carcinomas with increased vascularization and overexpression of VEGFi65 (7) . CCN1 may stimulate tumor vascularization by acting as an angiogenic inducer of endothelial cells, as VEGFi65 does (14) . In addition, CCN1 may act as a chemotactic, mitogenic, and matrix-remodeling factor as previously demonstrated in fibroblasts (12, (15) (16) (17) . However, little is know the regulatory role of CGN1 on the secretion of VEGFies, an angiogenic factor of reference, in human breast cancer cells.
In this annual report, we demonstrate that HRG-stimulated secretion of VEGF165 in human breast cancer cells requires an autocrine action of HRG on H£f?-2/neu-dependent signaling. In this regard, we generated a deletion mutant of HRG (HRG-M4) lacking the N-terminus sequence and the cytoplasmic-transmembrane region of HRG protein, which did not stimulate either HER-2/neu phosphorylation or VEGFies secretion. Interestingly, we provide the first evidence that CCN1 stimulates VEGF165 secretion independently of HRG overexpression and/or HER-2/neu activation. Moreover, we reveal that CCN1 synergistically enhances HRG-stimulated secretion of VEGF via activation of MARK and phosphatidylinositol 3'-kinase (PI-3'K)/protein kinase B (AKT) signaling pathways. In addition, we show that the involvement of CCN1 in VEGFies secretion can be attributed, at least in part, to its interaction with its integrin receptor avPa in human breast cancer cells. Figure 1a shows the basal level of the VEGF secretory isoform, VEGFies, in human breast cancer cell lines naturally overexpressing either HER-2/neu (SK-Br3 and BT-474) or HRG and CCN1 (MDA-MB-231, Hs578T) as compared to VEGFies secretion levels in MCF-7 breast cancer cells, which express physiological levels of HER-2/neu and HRG. Cells were seeded at a concentration of 5 x 10^ using 100-mm plates, and kept undisturbed until 75% confluence. Next, cells were starved for 24 h in serum-free medium, and maintained in 0.5% FBS for 48 h. Conditioned media were then collected and VEGFies expression was determined using the Quantakine human VEGF Immunoassay kit (R&D Systems, Minneapolis, MN, USA). VEGF values were normalized to total protein concentration in each plate. For calibration, we used human recombinant VEGFies provided by the supplier to construct a standard curve and to obtain absolute values of VEGF protein content. HRG-overexpressing MDA-MB-231 and Hs578T breast cancer cell lines demonstrated VEGF secretion levels (20.2 ± 3 and 28.8 ± 0.5 pg VEGF/^ig protein, respectively) beyond the up-regulation mediated by overexpression of IHER-2/neu in SK-Br3 and BT-474 breast cancer cell lines (10.4 ± 1.8 and 11.9 ± 0.1 pg VEGF/^ig protein, respectively), when compared with low HRG-and HEfl-2^neu-expressing MCF-7 cells (4.2 ± 0.2 pg VEGF/^ig protein). Next, we looked at MCF-7 cells that express low levels of HER-2/neu, and the same cells engineered to overexpress HRG (Figure lb) . The basal level of VEGF secretion was significantly increased in MCF-7/HRG transfectants (up to 15.7 + 1.3 pg VEGF/^ig protein in the MCF-7/T7 clone). This obsen/ation was not a clonal selection effect since a significant induction of VEGFies secretion was found in MCF-7 MCF-7/V, MCF-7/pBabe, MCF-7yT7, MCF-7/T8, IVICF-7/HRG, SK-Br3, and BT-474 were grown in IMEM/5% FBS until reactiing 75% confluence. Cells were then washed with PBS and solubilized in lysis buffer containing phosphatase and protease inhibitors. 50 |ig of protein per sample was subjected to Western blotting with p185'^^"-^"«"or P-Tyr antibodies. cells stably transduced with a pBabe retroviral vector containing the identical HRG cDNA (MCF-7/HRG cells). We examined by Western blotting the effect of forced expression of HRG on the expression of HER-2/neu protein in l\/ICF-7 breast cancer cells. The densitometric analysis suggested that HER-2/neu protein expression was up to 80% lower in the HRG-transfected MCF-7 cells (MCF-7/T7 and MC¥-7fT6 clones) or pBabe-HRG-transduced MCF-7 cells (MCF-7/HRG) than in matched control cells (MCF-7/V and IVICF-7/pBabe, respectively) or in wild-type MCF-7 cells (Figure 2 ). HRG overexpression resulted in a constitutive activation of HER-2/neu receptor, as evidenced by the p185"^''-^"«'' tyrosine phosphorylation levels observed in T7, T8, and MCF-7/HRG cells. The differences in p-\Q^HER-2/neu phosphorylatJOH between MCF-7/T clones reflected a variation of HRG expression between different clones (4) . Tyr-phosphorylated p-\Q5HeR-2/neu^as undotectable in MCF-7/V, MCF-7/pBabe, and wild-type MCF-7 cells. Importantly, p1Q^HER-2/neu phosphorylatlon levels in MCF-7 cells engineered to overexpress HRG were comparable to those found in SK-Br3 and BT-474 cells, which are known to overexpress HER-2/neu. These results indicate that high levels of HRG, independently of HER-2/neu overexpression, leads to up-regulation of VEGFies secretion in human breast cancer cells.
HRG-stimulated secretion of VEGFies requires an autocrine action of HRG on HEfl-a^neu-dependent signaiing.
HRG-induced responses are mainly mediated by the HER family of tyrosine kinase receptors (HER-2/-3/-4}. MCF-7/T clones and MCF-7/HRG cells produce high levels of HRG and thus have constitutively activated HER-2/neu receptors in spite of their low HER-2/neu receptors expression ( Figure 2 ). To investigate whether up-regulation of VEGFies secretion plays a role in HRGpromoted aggressive phenotype of breast cancer cells, we evaluated VEGFies levels in MCF-7 cells engineered to express a deletion mutant of HRG (HRG-4) incapable of promoting tumorigenicity (18) . HRG-M4 is a structural mutant of HRG p-2 that lacks N-terminus sequences (a putative nuclear localization signal -NLS-) and the cytoplasmic domain of the protein ( Figure  3A) . We previously demonstrated that HRG-4 protein, although stably expressed in MCF-7 cells, is sequestered into a cellular compartment and is not secreted into the culture media, thus preventing its autocrine action and HER-2/neu autophosphorylation. In addition, MCF-7/HRG-M4 cells did not become more aggressive or estrogen-independent, which was opposed to the phenotype arising from the full-length HRG protein (18) . Here, MCF-7 cells were transduced with the deletion mutant of HRG (MCF-7/HRG-M4 cells) or with the empty retroviral vector (MCF-7/pBabe) to circumvent the possibility of clone variations, and a stable MCF-7/HRG-M4 cell line was expanded after selection in puromycin containing media.
As expected, Western blotting analysis of MCF-7/HRG-M4 cells demonstrated neither down-regulation of pISS"^''-^"^'' receptor nor increase in pISS"^"-^™" tyrosine phosphorylation when compared with the matched control cells ( Figure 3^ . Interestingly, the transduction of MCF-7 cells with the HRG deletion mutant M4 did not cause any increase in VEGFies secretion when compared to the empty-vector infected MGF-7 cells ( Figure 3C ). (18, 19) . It is not clear, however, which functions can be attributed to the nuclear HRG and which functions, if any, can be independent of HER receptor activation. Therefore, we investigated whether secretion of HRG followed by activation of HER-2/neu receptor are necessary and/or sufficient molecular events in the HRG-promoted secretion of VEGFies. Our previous studies, using GFP-tagged HRG demonstrated a clear nuclear localization of the extracellular domain of the protein (18) . Interestingly, this localization was independent of the localization of the HER receptors, which have been previously identified in the nucleus of mammary epithelial cells, as assessed by co-localization experiments using confocal microscopy (data not shown). Therefore, we concluded that HRG must have a NLS at the NH2-terminus. Likewise, we identified a novel NLS in the extracellular domain of the HRG-protein between the fourth and the sixteenth amino acids, which does not fully resemble any of the known nuclear localization sequences, but has close homology to the NLS that is found in the p53 protein. In order to confirm its functionality, we deleted the first 33 amino acids of the HRG sequence, containing the putative NLS, and replaced it with GFP (NLS-) HRG. The HRGnegative, mammary epithelial breast cancer cell line MCF-7, was transfected with the (NLS-) HRG or full-length HRG-GFP fusion expression plasmids, and the localization of the fusion proteins was visualized by confocal microscopy. We observed a perinuclear localization of the HRG protein lacking the NLS sequence, which was markedly different from the clearly nuclear localization of the fulllength HRG protein (data not shown). These results confirm that HRG contains a functional NLS, which is essential for the translocation of the growth factor to the nucleus in MCF-7 cells. Based on these studies we set to identify if the nuclear localization of HRG was required for the up-regulation of VEGFies secretion. We found that the expression of the HRG-M1 increased the expression of VEGFies to even higher levels then the full-length HRG ( Figure 3Q .
We investigated whetiier the piienotypic ciianges that are mediated by deletion of the NLS of HRG are mediated through changes in the levels of HER-2/neu phosphorylation. Conversely to HRG-M4, as HRG-M1 protein is secreted, MCF-7/HRG-M1 cells did behave similarly to the MCF-7 cells infected with the wild-type HRG, and demonstrated down-regulation of HER-2/neu protein expression and constitutive activation of pISS"^''-^'™" ( Figure 3S ). These results indicate that the nuclear NHa-terminus of HRG acts as a suppressor rather than an activator of VEGFies secretion in human breast cancer cells. (20) . Conditioned media from six HRG antisense (HRG-AS) clones were analyzed for VEGFies secretion levels and compared to those found in empty vector-transfected MDA-MB-231 (MDA-MB-231/AS-V) cells. Secretion of VEGFies was significantly reduced in the majority of HRG-AS clones. In fact, VEGFies secretion was reduced by about 50% in MDA-MB-231/AS-31 transfectants (from 20.2 ± 2 in AS-V to 11.4 ± 0.5 pg VEGF/io-g protein) which express low to undetectable levels of HRG (20) . These results demonstrate that the decreased levels of HRG expression in the HRG-AS transfectants correlate with their decreased ability to secrete VEGFies.
Overexpression of CCN1 (CYR61) Stimulates Secretion of
VEGFies in MCF-7 Breast Cancer Cells. We have previously demonstrated that CCN1 is highly and selectively expressed in human breast cancer cells that naturally overexpress HRG (5, 12) . Accordingly, CCN1 overexpression was also found in MCF-7 human breast cancer cells engineered to overexpress HRG (5) . To determine whether overexpression of CCN1 was sufficient to stimulate secretion of VEGFies in the absence of HRG-and HER-2/neu overexpression, CCN1 was introduced in MCF-7 breast cancer cells, which are HRG-negative, and express physiological levels of HER-2/neu (7) . CCNI-overexpressing MCF-7/C2-6, MCF-7/C2-9, and MCF-7/C2-2 transfectants demonstrated VEGFies secretion levels (6.3 + 0.7, 6 .7 ± 0.1, and 10.2 ± 0.1 pg VEGF/|ig protein, respectively) significantly higher than those found empty vector-transfected MCF-7 cells (4.2 ± 0.8 pg VEGF/^g protein). We Several H£R-coupled signaling pathways including the MAPK pathway mediate VEGF by hypoxia (21) . Furthermore, inhibition of Pl-3'K, which has been shown to play an important role in eitB signaling, particularly with respect to HER-31HER-2 heterodimers, leads to inhibition of VEGF expression and angiogenesis (22, 23) . Therefore, we next tested the contribution of each particular pathway on CCN1-stimulated secretion VEGF165 in MCF-7 breast cancer cells. We first examined the total levels of MAPK and AKT and their phosphorylation status, i.e. activation, in the same protein lysates from CCNI-overexpressing MCF-7 cells in which VEGF165 secretion levels were found to be upregulated. Significantly higher levels of activated MAPK were observed MCF-7/C2-2, MCF-7/C2-6, and MCF-7/C2-9 clones but not in control cells, whereas the total level of MAPK was similar in CCNIoverexpressing and matched control cells (data not shown). Similarly, CCNI-overexpressing MCF-7/C2-2, MCF-7/C2-6, and MCF-7/C2-9 transfectants demonstrated an up-regulation of active AKT (as measured by antibodies specific for phosphor-Ser473 AKT) compared with matched control cells, whereas the level of total AKT were unchanged. The constitutive levels of phosphorylated AKT in MCF-7/CCN1 clones were at least 5-fold higher than in the parental MCF-7 cells, when the levels of phosphorylation were normalized to total AKT protein that was loaded (data not shown). These data demonstrate that stimulation of VEGF secretion in CCNI-overexpressing MCF-7 cells coincides with increased activation of MAPK and PI-3'K/AKT cascades. Moreover, these observations suggest that HER-2/neu, HRG, and CCN1 share similar signaling pathways, which may also account for the biological effect of CCN1 on the regulation of VEGF. Using U0126, a specific inhibitor of MEK-1 and MEK-2 activities (24), we investigated whether interfering with the MAPK signaling pathway would inhibit CCN1-enhanced VEGF165 secretion. U0126 treatment only affected MAPK signaling, as indicated by the complete inhibition of P-MAPK without affecting P-AKT, and concurrently decreased CCN1-enhanced secretion of VEGFies. In fact, the inactivation of the MAPK signal transduction pathway by U0126 resulted in a dramatic down-regulation of VEGFies secretion in CCNIoverexpressing MCF-7/C2-6 and MCF-7/C2-9 transfectants ( Figure 6 ). To evaluate the involvement of PI-3'K/AKT signaling in CCN1-enhanced secretion of VEGFies secretion, we tested whether LY294002, a competitive inhibitor of PI-3'K activity, would block CCN1-enhanced secretion of VEGFies-LY294002 exposure only affected PI-3'K signaling, as indicated by the complete inhibition of Ser-473 AKT without affecting P-MAPK, and concomitantly induced a significant decrease of VEGFies secretion ( Figure 6 ). These results indicate that, down-stream of CCN1, MAPKdependent signaling and PI-3'K-dependent AKT activity are participating in the transduction of signals that result in the increased secretion of VEGFies found in CCNI-overexpressing MCF-7 cells. Nonetheless, our results reveal that the MAPK signaling, as compared with PI-3'K/AKT pathway, plays a more important role in the up-regulation of VEGFies secretion of CCNI-overexpressing breast cancer cells. Decreases VEGF secretion Independently of HRG-lnduced activation of HER-2/neu. In the light of above observations, we hypothesized that CCN1 may be an anglogenic-promoting factor that acts independently of HRG overexpresslon. In this scenario, blockade of CCN1 expression will result in reduction of VEGFi65 secretion in cells that express high levels of HRG, such as the MGF-7/T7 transfectants. To block CCN1 expression, a eukaryotic expression vector was constructed with the GCN1 cDNA oriented from 3' to 5' end, that is, in an antisense direction, and subsequently transfected into HRGoverexpressing [\/ICF-7Ar7 clone. Several CCN1 antisense (T7/AC) clones were isolated and the presence of antisense CCN1 mRNA was confirmed by the RNAse protection assay (data not shown). Also generated were multiple clones of vector-transfected MCF-7/T7 (T7/AC-V) cells, all of which behaved similarly to the wild-type MCF-7/T7 clone. Four MCF-7/AC clones (T7/AC-2, T7/AC-4, T7/AC-6, and T7/AC-7) and one vector clone (T7/AC-V1) were characterized further. Conditioned media from AC-2, AC-4, AC-6, and AC-7 were collected and the secretion levels of VEGFies were determined as previously described. Figure 7 demonstrates the effect of antisense down-regulation of CCN1 expression on the basal level of VEGFi65 in the HRG-overexpressing MCF-7fT7 transfectants. Interestingly, blockade of CCN1 expression in HRG-overexpressing T7 transfectants led to dramatic decreases in HRG-induced VEGFies stimulation. However, the blockade of CCN1 expression in MCF-7 cells engineered to overexpress HRG was not able to reduce VEGFies secretion to the basal level observed in the wild type or MCF-7A/ cells. Importantly, the levels of HER-2/neu receptor expression and its phosphorylation status were unchanged In AS-CCN1 transfectants when compared with those found in T7 and T7/AC-V controls (data not shown). We can then postulate that CGN1 is necessa/y for the optimal stimulation of VEGFies secretion in HRG-overexpressing breast cancer cells.
CCN1 receptor Integrin Ovps plays a role
In HRG-and CCN1-stimulated secretion of VEGFies trough MARK signaling. CCN1 is a ligand of the integrin avpa (14) (15) (16) (17) . We have previously reported that a functional blocking antibody agains avpa is capable of blocking HRG induction of the aggressive phenotypes of the breast cancer cells (5) . It has been shown that CYR61 is an angiogenic ligand for avps integrin receptor (14) (15) (16) (17) . Thus, we have proposed that CCN1 can mediate tumor growth and angiogenesis of breast cancer cells in either autocrine or paracrine manner through its binding to the avps integrin receptor (7, 12) . Here, we decided to examine whether CCNMnduced secretion of VEGFies was associated with an increased integrin signaling. We compared six novel RGD peptidomimetic compounds having different integrin selectivity (Table 1) , for their inhibition of VEGFies secretion in CCN1-and HRG-overexpressing human breast cancer cells. Our results showed that S-247, the RGD antagonist with the highest affinity for avps integrin, significantly decreased VEGFies secretion in CCN1-overexpressing UCF-7 cells (Figure 8 ). Similarly, a significant inhibitory effect on VEGFies secretion was induced by S-247 integrin antagonist in HRG-overexpressing MCF-7/T7 transfectants. No significant effects were observed when RGD-based "peptidomimetics" directed against other integrins, such as llbllla, were used.
Among a variety of signaling cascades, the phosphorylation of focal adhesion kinase (FAK) and activation of the PI-3'K/AKT signaling pathway have been demonstrated to be involved in avPa-mediated adhesion, migration, and cell survival (25) (26) (27) . Accordingly, we have recently demonstrated that CGN1 overexpresslon in MCF-7 cells induces a prominent increase in the expression of FAK and significantly activates tfie PI-3'K/AKT signaling patfiway in MCF-7 cells (12) . Surprisingly, incubation of CCN1-and HRG-overexpressing IVICF-? cells with S-247 did not decrease the phosphorylation of either FAK or AKT (data not shown). Because integrins are involved in numerous pathways, S-247 is likely to inhibit signaling independently of FAK or AKT. Remarkably, we recently found that S-247 completely abolished I^APK hyperactivation in MCF-7 cells engineered to overexpress CCN1 or HRG (data not shown). Although CCN1 binds to several integrins, so far only the Wvps integrin has been shown to play a major role in breast cancer tumor vascularization and progression (13) . Our current results further imply that CCN1 is a downstream effector of HRG-promoted breast cancer neovascularization through its ability to enhance VEGFies secretion likely via activation of a avpa-MAPK signaling cascade in breast cancer cells. CCNI-overexpressing MGF-7/C2-6 and HRG-overexpressing MGF-7/T7 transfectants were exposed to 1 |iM SC56631, SC68448, S-247, S-196, and S-106 RGD-peptidomimetics for 48 h. VEGRes secretion was evaluated as described above. 11
KEY RESEARCH ACCOMPLISHIVIENTS
High levels of HRG, independently of HER-2/neu overexpression, leads to up-regulation of VEGFies secretion in human breast cancer cells.
HRG-stimulated secretion of VEGFies requires an autocrine action of HRG on HEfl-^'netfdependent signaling. However, HRG-stimulated secretion of VEGFies does not require a nuclear localization of HRG.
The growth factor-inducible immediate-early gene CCN1 (CYR61), a down-stream effector of HRG-induced breast cancer progression, is sufficients induce up-regulation of VEGFies in human breast cancer cells in the absence of HRG and HEfl-2/neu overexpression.
CGN1 (GYR61) enhances VEGFies secretion via activation of MARK and PI-3'K/AKT signaling cascades.
CCN1 (CYR61) is necessa/y for the maximal induction of HRG-dependent secretion of VEGFies in human breast cancer cells.
The activation of a CCNI/avpa/MAPK signaling network could drive VEGFies secretion in CCN1-and HRG-overexpressing human breast cancer cells.
CONCLUSIONS Role of Hereaulin in the Neovascularization of Breast Carcinoma
Among several angiogenic factors (VEGF, VEGF-related protein, VEGF-B, -0, -D, -E, placenta growth factor, and basic and acidic fibroblast growth factor), VEGF has been shown to be the major tumor angiogenic factor (28). VEGF can stimulate endothelial cell mitogenesis, and its overexpression has been detected in tumor cells, and was associated with high metastatic potential (28,29). Additionally, inhibition of VEGF signaling has been shown to impair tumor growth and suppress tumor metastasis (30). The present study was designed to examine the HRG-dependent regulation of the VEGF secretory isoform, VEGFies, in breast cancer cells that not overexpress the HER-2/neu oncogene. MCF-7 human breast cancer cells engineered to overexpress HRG offer the distinct advantage of studying \\gan6-HER-2/neu receptor activation in the absence of HER-2/neu overexpression. In this regard, our current analysis explored a uniquely different mechanism through ligand (HRG)-mediated transactivation of HER-2/neu signaling and up-regulation of VEGFies secretion. We used matched MCF-7 parent and HRG-transfected daughter human breast cancer cells, which differ in their HRG expression level, to evaluate the role of HRG on CDDP effectiveness. In addition, we performed parallel studies in retroviral HRG-infected MCF-7 cells to circumvent the possibility that phenomena due to effects other than HRG overexpression {i.e. clone specific) might be observed. Using this approach, we were able to directly compare VEGFies secretion in H£R-^nei^negative parental cells with low-expression of HRG to identical daughter cells with high-expression of HRG in vitro.
Several conclusions can be drawn from the results presented in this study: First, using a panel of breast cancer cell lines with constitutive HER-2/neu overexpression, HRG overexpression or engineered to stably overexpress HRG, we found that VEGFies secretion was significantly higher in HRG-overexpressing cells than in HER-2/neuoverexpressing and HRG-negative breast cancer cells. From the mechanistic point of view, it is clear that VEGFies secretion in HRG-overexpressing MCF-7 cells is not dependent upon HER-^^net/overexpression. In fact, the current data demonstrate a significant down-regulation of H£R-2/ne(7 protein levels following forced expression of HRG in MCF-7 cells. Thus, our results strongly suggest that HRG-induced transactivation of HER-2/neu signaling is sufficient to determine up-regulation of VEGFies secretion in breast cancer cells in the absence of HER-2/neu overexpression.
Second, we provide evidence that the pro-angiogenic functions of HRG can be attributed to different structural domains of the protein. We demonstrate that the deletion of both the N-terminus sequences (a putative nuclear localization signal -NLS-) and the cytoplasmic domain of HRG protein in the HRG-M4 structural mutant completely abolish the up-regulation of VEGFies secretion promoted by the full-length HRG. Of note, we recently reported that HRG-M4 blocks the aggressive phenotype that has been associated to with the full-length HRG (18) . Since the HRG-M4 protein is sequestered into a cellular compartment and is not secreted into the culture media, thus preventing its autocrine action and p185"^''-^''^"phosphorylation, the data derived from MCF-7/HRG and MCF-7/HRG-M4 cells strongly suggest that HRG-dependent transactivation of HER-2/neu signaling is sufficient to induce a prominent upregulation of VEGFies in human breast cancer cells. On the other hand, the deletion of the N-terminus sequences in the HRG-M1 mutant is not sufficient to reverse HRG-induced over-secretion of VEGFies, likely because this mutant, similarly to the full-length HRG, does not deprive breast cancer cells of pro-angiogenic transduction pathways provided by the activation of HER-2/neu signaling.
Third, the high levels of VEGFies secretion on MDA-MB-231 breast cancer cells, a natural model of HRG overexpression, were significantly diminished by transfection with antisense HRG cDNA. Interestingly, we recently demonstrated that blockade of HRG overexpression did suppress the aggressive phenotype of MDA-MB-231 breast cancer cells by inhibiting cell proliferation, preventing anchorage-independent cell growth, and suppressing the invasive potential of these cells in vitro (20) . More importantly, we observed a marked reduction in tumor formation, tumor size, and a lack of metastasis in vivo (20) . From our current observations, it is reasonable to suggest that blockade of HRG expression inhibits tumorigenicity and abolishes the metastatic process by perhaps inhibiting a large cascade of molecular events, including the secretion of the angiogenic factor VEGFiesSince CCN1 (CYR61) is also induced in HRG-overexpressing breast cancer cells (5) , and HRG promotes tumorigenicity in part via up-regulation of CCN1 (5), we further investigated whether CCN1 overexpression by itself was sufficient to bypass the previously observed tiER-2/neu requirement for HRG-enhanced secretion of VEGFiesForced expression of CCN1 in HER-2/neu-and HRG-negative MCF-7 human breast cancer cells resulted in a significant increase in the secretion of VEGFies, and this association occurred in the absence of HER-2/neu activation. Therefore, CCN1 is sufficient to up-regulate breast cancer cell secretion of VEGFies in the absence of HRG and HER-2/neu overexpression in breast cancer cells. Interestingly, CCN1 overexpression in HRG-and HER-2/neunegative MCF-7 cells was accompanied by activation of MARK and PI-3'K/AKT signaling pathways. Inactlvation of the MARK signaling using the specific inhibitor U0126 completely prevented CGN1-induced secretion of VEGFiesRharmacological inhibition of RI-3'K activity partially reversed CCN1-stimulated VEGFies secretion. These results indicate that, down-stream of CCN1, MARK and RI-3'K-dependent AKT activity are participating in the transduction of signals that result in the increased secretion of VEGFies found in GCN1-overexpressing MCF-7 cells. Moreover, these observations suggest that HER-2/neu, HRG, and CGN1 share similar signaling pathways, which may also account for the biological effect of CGN1 on the promotion of breast cancer aggressiveness. Interestingly, S-247, a potent antagonist of CCN1 receptor avps integrin, significantly decreased CCNMnduced secretion of VEGFies in MCF-7/CCN1 and MCF-7/HRG transfectants. The incubation of MCF-7/CCN1 transfectants with S-247 did not decrease the phosphorylation of either AKT or FAK or AKT. However, the functional blockade of avps integrin receptor completely abolished MARK hyperactivation in MCF-7 cells engineered to overexpress CCN1 or HRG. Because integrins are involved in numerous pathways, S-247 is likely to inhibit Wvps-dependent cellular signaling via MARK but independently of FAK or AKT. Although the exact mechanism(s) by which CCN1 enhances HRGstimulated VEGFies secretion is still unknown, it is tempting to postulate that CCNMnduced activation of otvPs-MARK signaling could be a new HEf?-2/neu-independent pathway involved in this phenotype. Importantly, the antisense down-regulation of CCN1 expression significantly decreased VEGFies secretion in HRG-overexpressing MCF-7/T7 transfectants. These results strongly suggest that a CCN1-dependent signaling through avps integrin may be necessarytor the maintenance of high levels of VEGFies secretion in HRG-overexpressing human breast cancer cells.
In summary, our current data provide new evidences about the role of HRG and its down-stream effector CCN1 (CYR61) as pro-angiogenic factors in human breast cancer cells. From a clinical perspective, current and future antagonists of specific integrin heterodimers, such those used in this study directed against avPs, or more specific anti-HRG and anti-CCN1 strategies, may have the potential to suppress tumorigenicity and metastasis of HRG-and CCN1-overexpressing breast carcinomas by decreasing VEGF-dependent breast cancer angiogenesis. 
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Contains important review articles -All papers peer-reviewed -Reports conference and symposium proceedings -International coverage and editorial board invasion, and metastasis (Lupu et al. 1995 , Tang et al. However, aggressiveness of human breast cancer is often 1995^ ^.tlas et al. 2003 . As a part of our efforts to describe related to the ability of the cells to overcome estrogen (E2) gene(s) directly involved in HRG-induced breast cancer requirements for growth, and in most cases to acquire antiaggressiveness, we recently isolated and identified CYR61, estrogen resistance (Nicholson & Gee 2000) . Thus, after the an angiogenic factor that is differentially expressed in ERinitial stages of breast cancer progression, tumors frequently negative, HRG-positive breast cancer cells (Tsai et al. 2000) . acquire resistance to E2 with concurrent amplification and/or CYR61 (CCNl), an extracellular matrix-associated protein dysregulation of growth factors/growth factor receptor. The of the cysteine rich 61/connective tissue growth factor/ mechanisms that enable the progression from E2 dependence nephroblastoma overexpressed (CCN) family which also to E2 resistance reinain poorly defined.
includes CCN2 (CTFG), CCN3 (NOV), CCN4 (WISP-1), Within this context, we have shown previously that CCN5 (WISP-2), and CCN6 (WISP-3), is a product of an expression of heregulin (HRG), a growth factor that activates immediate early gene that mediates cell adhesion, induces (O'Brien & Lau 1992 , Frazier el al. 1996 , Kireeva et al. 1996 , 1997 , 1998 , Wong et al. 1997 , Babic et al. 1998 , Kolesnikova & Lau 1998 , Chen et al. 2001 . Significantly, expression of CYR61 enhances neovascularization and tumor formation of human tumor cells in immunodeficient mice (Babic et al. 1998 , 1999 , Xic et al. 2001a .
CYR61 is a novel ligand for integrins, and signaling through integrin receptors such as a,.p" cc,.p,, allbB,, and a,,p, may explain many, if not all, of the known diverse functions of CYR61 (Kireeva et al. 1998 , Jedsadayanmata et al. 1999 , Chen et al. 2000 , Grzcszkiewicz et al. 2001 . Although CYR61 binds to several integrins, so far only the integrin Ovpj has been shown to play a major role in breast cancer tumor neovascularization and progression (Meyer et al. 1998, R Lupu et al. unpublished data) . More importantly, it has been demonstrated that overexpression of a,p, is a marker for poor prognosis in breast cancer (Gasparini et al. 1998) . In this regard, we have previously reported that a functional blocking antibody against a,p, is capable of inhibiting HRG induction of the aggressive phenotypcs of breast cancer cells (Tsai et al. 2(K) 0). Excitingly, we have recently found that forced expression of CYR61 in HRG-negative MCF-7 human breast cancer cells led to the up-regulation of the integrin receptor a..p, (Mendndez et al. 2002 (Mendndez et al. , 2003 . Furthermore, our more recent experimental data have established a novel role for CYR61 overexpression in determining protection of human breast cancer cells against paclitaxel (Taxol) , a microtubule-targcting drug that is among the most effective agents in the treatment of advanced breast cancer, refractory or non-responsive to endocrine manipulation (Seidman et al. 1995 , Perez 1998 . In addition to its effect on angiogenesis, CYR61 may play, therefore, an important role transmitting survival signals in either an autocrine or paracrinc manner through a CYR61/ o^Pi-primed regulatory loop in the absence of HRG overexpression.
This article provides a body of evidence demon.strating that aberrant expression of CYR61 promotes breast tumorigenesis and cancer progression by participating in the escape from anti-hormone control of cell growth. Also, we emphasize the functional significance of CYR61 and its mechanisms of action through the integrin receptor a,p, in human breast cancer cells. Ultimately, we speculate that targeting the CYR61/a,.p3-enhanced cell survival mechanism may prove therapeutically efficacious in the prevention or treatment of breast cancer.
Molecular pathology of CYR61 in breast cancer
CYR61, a molecular definition
CYR61 is a cysteine-rich, heparin-binding protein that is secreted and associated with the cell surface and the extracellular matrix (Yang & Lau 1991) , biochemical features that resemble the Wnt-1 proto-oncogene and a number of known growth factors (Yang & Lau 1991) . The human CYR61 cDNA encodes a protein 379 amino acids in length with a molecular mass of 42 kDa, and the gene is located on the short arm of chromosome 1 (Ip22-3I) (Charles et al. 1991 , Jay et al. 1997 . Of note, abnormalities of chromosome Ip have correlated with ER negativity and a poor prognosis in breast cancer (Hainsworth el al. 1992) , and other malignancies (Simon et al. 1991 , Shin et al. 1993 , Gehring el al. 1995 . CYR61 was originally identified by differential hybridization screening of a cDNA library of serum-stimulated BALB/c 3T3 fibroblasts (O'Brien et al. 1990 ). CYR61 is not expressed in quiescent fibroblasts, but it is transcriptionally activated within minutes after stimulation by serum, epidermal growth factor, basic fibroblastic growth factor (bFGF), platelet-derived growth factor, transforming growth factor-p, and 12-0-tetradecanoylphorbol 13-acetate (TPA) (Lau & Nathans 1985 , 1987 , Nathans et al. 1988 , O'Brien et al. 1990 . CYR61 belongs to the CCN gene family of angiogenic regulators, which consists of CCNl (CYR61), CCN2 (CTFG), CCN3 (NOV), CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3) (Lau & Lam 1999 , Brigstock et al. 2003 . All CCN proteins, including CYR6I: (1) display a high degree of conservation among family members and across species; (2) are cysteine rich and structurally similar to extracellular matrix-associated molecules; (3) are compo.sed of multifunctional modular domains with similar sequence homologies to insulin-like growth factor-binding protein, to von Willebrand factor type C repeat, to thrombospondin type 1 repeat, and to growth factor cysteine knots; and (4) have been shown to mediate functions as diverse as cell proliferation, migration, adhesion, cell survival, differentiation, and extracellular matrix formation. They also regulate more complex processes, such as angiogenesis and tumorigenesis (for reviews see Brig.stock 1999, Lau & Lam 1999 , Perbal 2001 .
Clinical relevance of CYR61 in human breast cancer
Increasing efforts have been devoted to defining the clinical relevance of cellular proteins that play a role in breast cancer progression. This interest has been particularly focused on proteins that are potential clinical indicators of disease prog-
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nosis. To determine whether expression of CYR61 may have any clinical relevance in breast cancer, we performed a pilot study using Western blot analysis on proteins extracted from paraffin sections of breast tumor biopsies. In about 40% of the tumor specimens, all of which were ER-negative invasive breast carcinomas, we found high expression of the CYR61 protein (Tsai et al. 2000) . Additional studies revealed that CYR61 was present in about 30% of breast tumor specimens as determined by immunohistochemistry, while no staining was observed in normal components of the biopsies (Tsai et al. 2000) . Using Northern blot analysis, Xie et al. (2001^) ) also found CYR61 to be highly expressed in 36% of primary breast tumors. Sampath et al. (2001) showed that CYR61 was overexpressed in 70% of breast cancer patients with infiltrating ductal carcinomas of the breast and CYR61 was localized exclusively to hyperplastic ductal epithelial cells. More recently, overexpression of CYR61 was found in 39% of primary breast cancers using quantitative real-time PCR assay (Xie et al. 2001ft) . In this study, a significant correlation was found between elevated levels of CYR61 and advance stage and size of the primary tumor and lymph node involvement at the time of removal of the primary tumor.
All these results, taken together, indicate that prominent expression of CYR61 may play a role in the process of breast cancer development and might serve as a valuable tool for monitoring the tumor status of breast cancer patients. Further studies, however, should attempt to determine whether measurement of CYR61 at diagnosis could provide prognostic data and suggest those tumors that might be responsive to therapy. Incidentally, our group has extensively analyzed the aberrant signaling pathways that are activated by CYR61 overexpression which, hopefully, may offer new valuable therapeutic targets in breast cancer.
Expression and regulation of CYR61 in human breast cancer cell lines
We have demonstrated that expression of the growth factor HRG, a growth factor that activates the erbB-2/3/4 receptor network signaling, is highly associated with an aggressive progression of breast cancers to hormone independence, antiestrogen resistance, invasion, and metastasis (Lupu et al. 1995 , Tang et al. 1996 , Hijazi et al. 2000 . To identify genes that are involved in the HRG induction of breast cancer progression, a number of genes were isolated and cloned by differential expression in the MDA-MB-231 model, a human breast cancer cell line that naturally overexpresses HRG. Sequence and homology analyses evidenced that one of these genes was the human homologue of a mouse immediate early response gene, Cyr61. CYR61 was highly and selectively expressed (a 5-to 25-fold increase in the CYR61 mRNA level) in MCF-7 human breast cancer cells engineered to overexpress HRG (HRG-transfected MCF-7 clones T2, T6, T7, and T8) (Tang et al. 1996 , Harris et al. 1998 , but was almost undetectable in vector-transfected MCF-7 cells (Tsai et al. 2000) . HRG-positive MDA-MB-231 cells also expressed high levels of CYR61 mRNA. Western blot and immunohistochemical analyses using an anti-CYR61 polyclonal antibody demonstrated that the CYR61 protein was selectively up-regulated in human breast cancer cells forced to overexpress HRG. Moreover, when the basal level of CYR61 expression was examined in a panel of human breast cancer cell lines, we found that CYR61 mRNA and protein were highly expressed in MDA-MB-231, Hs578T, BT549, and MCF-7/HRG cells, all of which are HRG-overexprcssing and ER-negative cells (Tsai et al. 2000) . Conversely, CYR61 levels were low or undetectable in cells that do not express HRG and are ER negative, including MCF-7, ZR75B, T47D, and BT-474 cells (Tsai et al. 2000) . These data are summarized in Table 1 . Our data undoubtedly demonstrated that high level of CYR61 expression tightly correlates with HRG overexpression and inversely correlates with ER expression. Moreover, the expression of CYR61 strongly correlates with vimentin expression, a known marker for invasiveness (Thompson et al. 1992) , and is associated with the ability of breast cancer cells to invade //) vitro and mctastasize /;; vivo. Hence, there exists a tight correlation between HRG overexpression, CYR61 up-regulation, and breast cancer progression.
In our evaluation of CYR61 in breast tumor biopsies (Tsai et al. 2000) , CYR61 expression was closely correlated with tumor progression and ER negativity. It has been recently shown that CYR61 overexpression is associated with more advanced breast cancer disease. However, although the sample number was relatively small, Xie et al. (2001 fl) showed a significant correlation between CYR61 expression and ER positivity, even though ER expression is known to be an indicator of good prognosis for breast cancer (Brown et al. 2000) . Similarly, Sampath et al. (2001) suggested that increased levels of CYR61 in ER-positive breast tumors might contribute to E2-driven tumorigenesis in vivo. Some of these conflicting observations may be due to different methodologies used to quantify CYR61 expression, such as moderately sensitive Northern blots detecting CYR61 expression in malignant and non-malignant breast epithelium (Xie et al. 2001a ) versus highly sensitive and breast epithelium-specific immunohistochemical analysis (Tsai et al. 2000) . These somewhat mystifying results led us to use a systematic in vitro and in vivo approach assessing the actual relationship of CYR61 and ER-signaling pathways in human breast cancer cell growth and progression.
Previous studies showed that murinc Cyr6I is inducible by E2 and tamoxifen in the uterus of ovariectomized rats (Rivera-Gonzalez el al. 1998). However, it is not clear how CYR61 is regulated in human breast cancer, except that it has been indicated that CYR61 is E2 inducible, and that tamoxifen inhibited its mRNA expression in human breast cancer cells (Xie et al. 2001 A) . Therefore, we investigated in more detail how CYR61 expression is regulated in both ER-positive and ER-negative breast cancer cells (Tsai et al. 20026) . We were the first group to establish that expression of CYR61 at both the mRNA and protein levels was inducible by E2 in E2-dependent breast cancer cells . Moreover, we demonstrated that treatment of E2-depleted cells with the anti-estrogens tamoxifen and ICI 182 780 caused a marked up-rcgulation of CYR61 mRNA.
Tamoxifen, a well-known anti-estrogen, functions as an agonist and antagonist through both transcriptional activation domains (AFl and AF2) of ER. ICI 182 780, a pure antie.strogen, acts solely as an antagonist through the AFl domain (McGregor & Jordan 1998) . Interestingly, the combination of E2 with either anti-estrogen abrogated the activation of CYR61 gene expression. We ob.served that CYR6I protein expression was also up-regulated (over 10-to 20-fold) by E2, tamoxifen and ICI 182 780 in MCF-7 cells. Other important regulators of CYR61 expression in breast cancer cells that we found were the phorbol ester TPA, vitamin D, and retinoic acid. TPA cau.sed positive regulation of CYR61 expression in ER-positive MCF-7 cells. Vitamin D induced a transient stimulatory effect on CYR61 gene expression. Finally, the differentiating agent, retinoic acid, down-regulated CYR61 expression in MCF-7 breast cancer cells. In cells that acquire E2 independence but still express ER, such as MCF-7 cells transfected with HRG (MCF-7/ HRG), E2 induced CYR61 expression to a much lower extent; conversely, these agents no longer mediated the expression of CYR61 in MDA-MB-231 cells, which express high levels of endogenous CYR61. This finding was consistent with the phenotype of the MDA-MB-231 cell line, which is ER negative, E2 independent, anti-estrogen resistant, highly invasive, and mctastatic in vivo.
Together, our results proved that the fold induction of CYR61 by E2 and/or anti-estrogen agents coincides with the endogenous levels of CYR61 expression and is inversely correlated with the levels of ER expression in human breast cancer cells. Moreover, our results were in agreement with our knowledge that CYR61 promotes tumor growth, and that anti-estrogen agents have a positive impact on breast cancer cells expressing low levels of CYR61 (ER-positive breast cancer cells); conversely, these agents have no significant effect on cells that express high levels of CYR61 (ER-negative brea.st cancer cells).
CYR61 is sufficient to promote acquisition of E2 independence and anti-estrogen resistance in human breast cancer cells
CYR6I is differentially expressed in HRG-positive, invasive, and mctastatic human breast cancer cells (Tsai et al. 2000) . Moreover, enhanced expression of CYR6I correlates with lack of ER expression. To determine whether ectopic expression of CYR61 alone, in HRG-negative brea.st cancer cells, is necessary and/or sufficient to confer some biological activities induced by HRG, such as loss of E2 respon.se and acquisition of anti-estrogen resistance, MCF-7 human breast cancer cells, which are ER positive, E2 reponsive in vitro, and are growth inhibited by many anti-estrogen drugs (Nicholson el al. 1995) , were engineered to overexpress CYR61. In anchorage-dependent assays, our breast cancer models of CYR61 overexpression showed a growth advan-tage in E2-depleted media, having a three-to fivefold increase in growth as compared with control cells . These results illustrate that overexpression of CYR61 provides a growth advantage to bypass the 'normal' E2 requirement for the proliferation of MCF-7 human breast cancer cells (Pratt & PoUak 1993 . Interestingly, CYR61-overexpressing MCF-7 cells were still responsive to E2, resembling one of the clinical phenotypes found in women suffering from breast cancer. When MCF-7/ • CYR61 cells were treated with tamoxifen or ICI 182 780, both anti-estrogens reduced only the growth induced by E2 in MCF-7/CYR61 cells. However, they were unable to block the E2-independent growth of the MCF-7/CYR61 cells, indicating that CYR61 provides a true growth advantage that cannot be inhibited by anti-estrogen agents. In other words, both anti-estrogens inhibited the growth of the cells only to the basal levels promoted by overexpression of CYR61, whereas they were not able to reduce cell growth to the same level achieved in the wild-type MCF-7 cells in the absence of E2. These in vitro experiments revealed, therefore, that CYR61 overexpression can stimulate cell growth of E2-dependent cells in the absence of E2s resuUing in cells becoming E2 independent. On the other hand, E2s further enhances cell proliferation of CYR61-overexpressing cells, indicating that these cells, although independent of E2, are still responsive to E2. Therefore, it is likely that overexpression of CYR61 alone most probably accounts for the growth advantage observed in MCF-7/CYR61 cells in E2-depIeted culture conditions. A possible mechanism to acquire E2-independent and anti-estrogen-resistant phenotypes acts via the loss of ER expression and/or ER function. Within this context, we have observed that the basal level of ERa expression is markedly reduced (30-50%) in MCF-7/CYR61 cells (Tsai et al. 2002a) . These results indicate that CYR61 expression correlates with the loss of ER expression, consistent with our previous finding that CYR61 expression is closely associated with tumor progression and ER negativity in tumor biopsies (Tsai et al. 2000) . We next examined whether CYR61 promotes loss of ER function by assessing the regulation of several well-documented E2-responsive genes. Since we previously demonstrated that the loss of progesterone receptor (PgR) regulation by E2 attests for the loss of ER function (Saceda et al. 1996 , Tang et al. 1996 , our studies in MCF-7/ --j CYR61 cells were focused on E2 regulation of ERa and PgR expression. Although the level of ERa expression was lowered, E2 exposure further down-regulated the expression of ERa in CYR61-overexpressing MCF-7 cells, and induced a marked up-regulation in PgR mRNA expression. Similarly, we observed E2-induced up-regulation of cathepsin D and trefoil factor 1 (TFFl, formerly pS2), which have been shown to be up-regulated by E2 in MCF-7 cells (Cavailles et al. 1988 , Weaver et al. 1988 . These data support the notion that ERa is still a functional receptor in MCF-7/ CYR61 cells, although these cells are E2 independent and the level of ERa expression is lower than that in the parental cells.
CYR61 enhances a metastatic phenotype by promoting cell proliferation in soft agar, cell migration and invasion, and IVIatrigel outgrowth of breast cancer cells
Acquisition of a transforming phenotype is often correlated with the ability of cells to grow in an anchorage-independent fashion. It is well established that MCF-7 cells are not anchorage independent in the absence of E2. Colonies observed, if any, represent the background level for the colony formation assay. We and others observed that MCF-7 engineered to overexpress CYR61, in the absence of E2, formed large colonies in soft agar assays (Xie et al. 2001a , Tsai et al. 2002a . As expected, E2 exposure induced anchorage-independent growth of control MCF-7 cells, which was completely blocked by anti-estrogen. Interestingly, E2 exposure also slightly enhanced the colony formation in the CYR61-overexpressing MCF-7 cells, an E2-driven effect that was not reversed in the presence of the pure anti-estrogen ICI 182 780 (Tsai et al. 2002a) . Xie et al. (2001a) noted that tamoxifen blocked the E2-stimulated colony formation in MCF-7/CYR61 cells. In contrast, we demonstrated that both tamoxifen and ICI 182 780 enhanced colony formation of MCF-7/CYR61 cells (Tsai et al. 2002a , R Lupu and M-S Tsai unpublished data). Nonetheless, all these studies clearly indicate that forced expression of CYR61 promotes anchorage-independent clonogenic growth of MCF-7 cells. Using vitronectin-coated Boyden chambers, an in vitro assay to quantitate the invasive potential of tumor cells (Albini et al. 1987) , Xie et al. (2001a) established that CYR61 stably transfected cell lines show significantly increased migration compared with the empty vector-transfected cells. In our experiments, we addressed the question whether CYR61 is a direct downstream regulation of HRG-induced metastatic properties in human breast cancer cells. For these studies we used HRGtransfected MCF-7 cells (Tang et al. 1996 , which have been shown to migrate through collagen in a Boyden chamber assay, and a CYR61-neutralizing antibody (Tsai et al. 2000) . The anti-CYR61-neutralizing antibody inhibited migration of MCF-7/HRG cells in a dose-dependent manner. Similar results were observed in other invasive, HRG-overexpressing breast cancer cells, such as MDA-MB-231, Hs578T, and BT549. These studies demonstrated that CYR61 overexpression influences cell migration of MCF-7 cells, and suggest an association between the activation of CYR61 expression in human breast cancer and the invasive potential triggered by HRG. Recently, we established that MCF-7/CYR61 cells show extensive outgrowth in Matrigel (Tsai et al. 2002a) , an in vitro assay that is frequently www.endocrinology.org employed as a reliable system to assess //; vitro invasivencss of breast cancer cells (Sommer et al. 1994 , Hijazi el al. 2000 . Significantly, CYR61 overexpression promoted outgrowth of MCF-7 cells in the Matrigcl matrix in the absence of E2, the colonies appearing large and irregular in shape. In contrast, control cells were not able to migrate through and proliferate in the Matrigcl matrix even in the presence of E2, suggesting that CYR61 can induce an invasive phenotype of breast cancer cells in an E2-independent manner (Tsai et al. 2002a ).
CYR61 promotes tumorigenesis and neovascularization
On the basis of our //; vitro studies indicating that overexpression of CYR61 promotes anchorage-independent clonogenic proliferation in soft agar as well as cell migration and invasion, all of which are characteristics of an aggressive breast cancer phenotype, we envisioned that CYR61 overexpression should promote tumor development and neovascularization. Recently, we reported that MCF-7 cells transfected with CYR61 developed large and more vascularized tumors in ovariectomized nude mice (Tsai et al. 2002<7) . These tumors grew independently of hormonal stimulation, supporting our in vitro data suggesting that the MCF-7/CYR61 cells had a growth advantage in the absence of E2. The tumors developed for CYR61-overexpressing cells were highly vascularized. In agreement, overexpression of CYR61 promoted the expression of another important regulator of neovascularization, vascular endothelial growth factor (VEGF). Xie et al. (200 lo) also described that MCF-7 breast cancer cells forced to overexpress CYR6I developed larger and more vascularized tumors in nude mice. Another interesting finding of this study is that overexpression of stably transfected CYR6I in the normal breast epithelial cell line MCF-12A, which does not normally express CYR6I, resulted in tumor formation in nude mice. Taken together, these in vitro and in vivo findings suggest that prominent expression of CYR61 may facilitate transformation of breast tissue, and indisputably demonstrate that overexpression of CYR61 in MCF-7 cells promotes tumorigenesis in the absence of hormonal stimulation.
Therapeutic perspectives of CYR61 in breast cancer
CYR61 overexpression promotes breast cancer cell resistance to Taxol-induced cell death: involvement of the phosphatidylinosltol 3'-kinase (PI3'-kinase)/ protein kinase B (AKT) pro-survival pathway
We have previously demonstrated that HRG-overexpressing cells showed a marked increase in sensitivity to the topoisomerase II inhibitors doxorubicin and etoposide (Harris et al. 1998) . Interestingly, virtually every conventional cytotoxic anti-cancer drug has been 'accidentally' discovered to have anti-angiogenic effects in various in vivo models (Kerbel et al. 2000 , Miller et al. 2001 . Recently, the tumor cell microcnvironment has been found to have a significant bearing on the survival of tumor cells following exposure to a wide variety of anti-neopla.stic agents, prior to the acquisition of known drug resistance mechanisms. Accordingly, it has been recently demonstrated that some angiogenic factors such as VEGF and bFGF significantly reduced the potency of chemotherapy (Lissoni et al. 2000 , Zhang et al. 2001 , Tran et al. 2002 . Because of the pro-angiogenic abilities of HRG and CYR61, we hypothesized that HRG could also act directly -or indirectly through CYR61 -as a survival factor for brca.st carcinoma cells modifying chemotherapy effectiveness. In this regard, we recently examined whether CYR61, in the absence of HRG overexpression, may play a role in the breast cancer cell responses to chemotherapyinduced damage. Significantly, we observed that CYR61 overexpression rendered MCF-7 cells resistant to paclitaxel (Taxol) in both anchorage-dependent and soft agarose colony-formation assays (Mcndndcz et al. 2002 (Mcndndcz et al. , 2003 . Because apoptosis is the predominant mechanism of cytotoxicity induced by chemotherapeutic agents, we analyzed whether the failure of CYR61-overexpressing breast cancer cells to activate apoptosis may account for CYR61-promoted Taxol resistance. When MCF-7/CYR61 cells were examined for apoptosis-related parameters after Taxol exposure, no signs of the classical DNA laddering formation were observed in CYR61 transfectants compared with control cells. Accordingly, CYR61 overexpression induced a dramatic decrease in the number of TUNEL-positive cells compared with Taxol-treated control cells (Menendez el al. 2002 (Menendez el al. , 2003 . It has been shown that Taxol-induced apoptosis involves a dose-and time-dependent accumulation of the tumor suppressor gene p53 and the inhibitor of cyclindependent kinases, p21*'\''if"i 'i (Bla.sgosklonny et al. 1995 , Giannakakou et al. 2001 . Our preliminary experiments, however, noted a reduced ability of the MCF-7/CYR61 cells to induce p53 expression in response to Taxol exposure, suggesting that CYR61 overexpression could suppress Taxolinduced apoptosis by interfering with the function of wildtype p53 in human breast cancer cells .
Simultaneously to Taxol resistance, MCF-7/CYR61 cells showed cross-resistance to wortmannin and LY294002, two pharmacological inhibitors of the PI3'-kinase activity. Interestingly, we have demonstrated that CYR61-overexpressing MCF-7 cells undergo up-regulation of the PI3'-kinase/AKT kinase pro-survival pathway (Tsai et al. 2002f, Menendez et al. 2002 , 2003 . Because several studies have recently indicated that alterations in the PI3'- -Related Cancer (2003) 10 141-152 kinase/AKT signal transduction pathway can modulate cell sensitivity to Taxo! (Mitsuuchi et al. 2000 , Hu et al. 2002 , MacKeigan et al. 2002 , it is likely that a new important function of CYR61 in human breast cancer is the promotion of cell survival by activating anti-apoptotic signaling pathways such as those composed of PI3'-kinase and the serine/threonine kinase AKT. Accordingly, the protective effect of CYR61 against Taxol-induced cytotoxicity was abolished under culture conditions inhibiting PI3'-kinase activity . These findings establish a novel role for CYR61 in determining protection of human breast cancer cells against Taxol-induced apoptosis through the activation of the PI3'-kinase/AKT pro-survival pathway.
Endocrine
The 'CYRei-ttvPa integrin connection': a new molecular therapeutic target in human breast cancer
Depending on the biological context and model system, CYR61 can induce disparate functions. However, most of the CYR61-promoted effects are mediated via its direct binding with the integrin receptor cCvPa-Thus, we speculated whether CYR61-enhanced breast cancer progression requires expression of the integrin receptor CCVPJ for its actions. Indeed, we observed that the level of Ovps was significantly augmented in MCF-7 engineered to overexpress HRG compared with control cells (Tsai et al. 2000) . Moreover, we determined that blockade of this integrin receptor using LM609, a monoclonal antibody directed against a^%, dramatically blocked the Matrigel outgrowth of HRG-overexpressing breast cancer cells in a dosedependent fashion (Tsai et al. 2000) . These results indicated, for the first time, that the functional OvP, integrin is required for maintaining the invasive capacity of HRGexpressing cells, and that the aggressive phenotypes induced by HRG are mediated, in part if not entirely, through the interaction of CYR61 with integrin OvPs.
Recently, we assessed whether CYR61, independent from HRG expression, affected the levels of the integrin receptor OvPs. Use of a monoclonal anti-0tvp3 antibody demonstrated that, similarly to MCF-7/HRG cells, HRGnegative CYR61-overexpressing MCF-7 cells stained positively for OvPs, whereas no significant staining was observed in control cells . To the best of our knowledge, this is the first indication showing that activation of OvPs expression in human breast cancer epithelial cells can be achieved solely by CYR61 overexpression, irrespective of HRG status. More importantly, the most recent data from our laboratory indicate that CYR61-promoted breast cancer cell survival and Taxol resistance are phenotypes associated with an increased ayBj integrin signaling. Using SC56631, a previously characterized synthetic chemical peptide mimetic based upon the ctvP, ligand, Arg-Gly-Asp (RGD motif) (Engleman et al. 1997) , we observed a marked decrease in the cell viability of HRG-and CYR61-overexpressing breast cancer cells but not in HRG-and CYR61-negative control cells. Furthermore, sub-optimal doses of SC56631 completely abolished Taxol resistance in MCF-7/CYR61 cells, as Taxol-induced cytotoxicity returned to the basal level observed in CYR61-negative control cells. Moreover, the nature of the interaction between SC56631 and Taxol was shown to be synergistic in CYR61-overexpressing breast cancer cells . These results, together, strongly suggest that therapies depriving CYR61-overexpressing cells of their OvPs signaling dramatically decrease cell survival and chemoresistance.
Integrin a,P3 has been implicated in the pathophysiology of malignant tumors. In addition to its expression on the surface of angiogenic endothelial cells, integrin OvPa is expressed on the surface of tumor cells in a variety of cancers. In breast cancer, the integrin cCvPa characterizes the metastatic phenotype, as its expression is up-regulated in invasive tumors and distant metastases (Gasparini et al. 1998) . Thus, independent of its role in tumor angiogenesis, the integrin OCPJ is functionally implicated in the pathogenesis of breast cancer. Integrin signals are involved in diverse biological responses, including angiogenesis and tumor progression, as well as in a variety of cellular activities, including cell migration, proliferation, and survival. Of interest, integrin signaUng has recently been shown to modulate cancer cell responses to chemotherapeutic agents (Aoudjit & Vuori 2001) . Specifically, interactions between cell surface integrins and extracellular matrix components have been shown to be responsible for this phenomenon of innate drug resistance, which we have termed cell adhesion-mediated drug resistance (Damiano et al. 1999 , Gilmore et al. 2000 . Thus, signal transduction pathways initiated by integrin Ugation may be potential bridge points for inhibiting cell survival during cytotoxic drug exposure. Among the signaling molecules involved in integrin-mediated cell survival is focal adhesion kinase (FAK), which becomes activated following integrin ligation and may in turn activate down-stream survival pathways such as those composed of PI3'-kinase and the serine/threonine kinase AKT (King et al. 1997 , Gilmore et al. 2000 , Lee & Juliano 2000 . Likewise, we have recently demonstrated that CYR61 overexpression in MCF-7 human breast cancer cells induces a significant increase in the expression of FAK . On the basis of these studies it is tempting to postulate that upregulation of CYR61 in breast cancer cells may drive breast cancer cell survival and chemoresistance by emitting a proliferative and/or survival input via the integrin receptor a^% and FAK, which might integrate signals from CYR61 to the PI3'-kinase/AKT pro-survival pathway. Importantly, CYR61 can also promote cell survival of angiogenic endothelial cells through interaction with integrin a^Ps (Leu et al. 2002) .
www.endocrinology.org Ttie 'CYR61/oc,.p, connection' thu,s appears to provide a promising molecular target for breast cancer disease that should permit a potentially synergistic strike against the tumor and its supporting vasculature (Fig. 1) .
Conclusions
Breast cancer often progresses from an E2-dependent, nonmetastatic, anti-estrogen-sensitive phenotype to an E2-independent, anti-estrogen-resistant, highly invasive and metastatic phenotype. Our results have demonstrated that CYR61 is a tumor-promoting factor that also acts as a key regulator of breast cancer progression. Significantly, in our current studies we have demonstrated that the angiogenic factor CYR61 is sufficient (1) to induce E2 independence and anti-estrogen resistance, (2) to promote invasiveness in vitro, and (3) to induce tumorigenesis and neovascularization in vivo. Our results further suggest that signaling through OvPa integrin allows for the maintenance of the cell viability of human breast cancer cells treated with Taxol. Although the exact mechanism through which the angiogenic factor CYR61 promotes cell survival and Taxol resistance in breast cancer cells is still unknown, it is tempting to postulate that CYR61-induced activation of the a,.p7FAK/PI3'-kina.se/ AKT pro-survival signaling could be a/the pathway involved in this phenotype. New anti-CYR61 and/or anti-a,.p, therapeutic strategies may prevent vessel growth simultaneously rendering breast cancer cells more sensitive to Taxol-based chemotherapy.
In summary, our current approach indicates that activation of the CYR61/a,,p, signaling network could drive breast cancer cells to escape hormonal requirements providing compensatory survival pathways that ultimately allow the acquisition of breast cancer chemoresistance. As knowledge of CYR61 involvement in breast cancer processes increases, the 'CYRei/ccp,' connection in both angiogenic endothelial cells and tumor cells appears to be an increasingly attractive target for drug development (Fig. 2) . Our data provide a starting point to exploit the potential anti-angiogenic and antitumor effects of highly specific a,.p, inhibitors. 
by regulating endothelial recruitment tumor neovascuiarization in a paracrine fashion through an OvPs-dependent mechanism, (3) by co-ordinating tumor epithelial cell migration as a chemokinetic factor, and (4) 
